NCT00048152
Completed
Phase 3
A Randomized, Open-label Study Comparing the Effects of Low-dose Cyclosporine vs Cyclosporine Withdrawal on Renal Function in Kidney Transplant Patients Treated With CellCept and Daclizumab
ConditionsKidney Transplantation
Overview
- Phase
- Phase 3
- Intervention
- Corticosteroids
- Conditions
- Kidney Transplantation
- Sponsor
- Hoffmann-La Roche
- Enrollment
- 539
- Primary Endpoint
- Renal function (as measured by GFR)
- Status
- Completed
- Last Updated
- 9 years ago
Overview
Brief Summary
This study will compare kidney function in kidney transplant patients following treatment with various combinations of Zenapax, CellCept, corticosteroids, and Neoral (Cyclosporine). The anticipated time on study treatment is 6-12 months, and the target sample size is 500+ individuals.
Investigators
Eligibility Criteria
Inclusion Criteria
- •adult patients greater than 18 years of age
- •recipients of primary kidney transplant
- •single-organ recipients (kidney only)
Exclusion Criteria
- •previous treatment with Zenapax
- •history of malignancy (except localized skin cancer)
Arms & Interventions
1
Intervention: Corticosteroids
1
Intervention: Neoral
1
Intervention: Zenapax
1
Intervention: mycophenolate mofetil [CellCept]
2
Intervention: Corticosteroids
2
Intervention: Neoral
2
Intervention: Zenapax
2
Intervention: mycophenolate mofetil [CellCept]
3
Intervention: Corticosteroids
3
Intervention: Neoral
3
Intervention: mycophenolate mofetil [CellCept]
Outcomes
Primary Outcomes
Renal function (as measured by GFR)
Time Frame: 12 months post-transplant
Secondary Outcomes
- AEs, OIs, malignancies, deaths(Throughout study)
- Patient and graft survival \n(12 months post-transplant)
- Proportion of patients with biopsy-proven rejection; treatment failure.(6 and 12 months post-transplant)
Similar Trials
Completed
Phase 3
Study Evaluating Sirolimus in Kidney Transplant RecipientsGraft vs Host DiseaseKidney TransplantationNCT00195273Wyeth is now a wholly owned subsidiary of Pfizer61
Completed
Phase 4
Everolimus in Combination With Cyclosporine Microemulsion in de Novo Renal Transplant RecipientsKidney TransplantationNCT00170885Novartis
Terminated
Phase 4
Efficacy and Tolerability of Full Dose Enteric-coated Mycophenolate Sodium, in Addition to Cyclosporine for Microemulsion Reduced Dose, in Maintenance Renal Transplant RecipientsKidney TransplantationNCT00434590Novartis Pharmaceuticals10
Completed
Not Applicable
Comparing Everolimus and Sirolimus in Renal Transplant RecipientsRenal FailureNCT01976390Ohio State University60
Completed
Phase 4
Kidney Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Rapamune (Sirolimus) in Kidney Transplant RecipientsKidney TransplantationNCT00121810Hoffmann-La Roche305